decisionhealth Newsletters, Coder Pink Sheets - 2008 Issue 9 (September)
Lexiscan maker to apply for J-code; for now, though, use J3490
Subscribe or sign in to view the full article.
Article Overview
This short article explains a cardiology coding issue related to a newly released stress-agent drug used in nuclear testing. It focuses on the temporary billing approach, the anticipated move toward a product-specific HCPCS code, and why payers may scrutinize claims during the interim period. The content is relevant for cardiology practices, office-based nuclear medicine billing staff, and coding professionals following HCPCS drug code updates.
Why This Topic Matters
Healthcare providers and coders need to know how to report a newly marketed drug before a permanent HCPCS identifier is assigned, especially when claims processing and payer review may be affected.
What You Will Learn
- The billing challenge created when a newly marketed drug does not yet have a product-specific HCPCS code.
- Why temporary drug code assignment and payer response can affect claim processing.
- How the issue differs between office-based nuclear testing and hospital-based settings.
- The general timeline considerations for future HCPCS code changes.
Who Should Read This
- Cardiology coders
- Billing staff
- Compliance managers
- Office-based cardiology practices
- Nuclear medicine billing professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com